GOLD B (n = 51) | GOLD D (n = 19) | p - value | |
---|---|---|---|
Demographics | |||
Gender (% Male) | 75.6 | 52.6 | 0.15 |
BMI (Kg/m2) | 27.0 [16.2–44.8] | 27.7 [21.7–48.5] | 0.32 |
FFMI (Kg/m2) | 18.3 [8.8–24.0] | 17.6 [11.7–27.0] | 0.75 |
Exacerbations (1 year prior) | 0.0 [0.0–1.0] | 2.0 [0.0–4.0] | <0.0001 |
Patient reported outcomes | |||
SGRQ total | 41.1 (15.5) | 50.0 [22.2–82.3] | 0.001 |
SGRQ symptoms | 54.6 (19.9) | 61.0 (17.5) | 0.24 |
SGRQ impact | 26.3 [2.1–71.6] | 42.4 [4.6–60.1] | 0.05 |
SGRQ activity | 59.3 [0.0–100.0] | 78.1 [22.5–100.0] | 0.003 |
CAT | 15.5 [9.0–35.0] | 20.0 [9.0–37.0] | 0.018 |
CES-D | 12.0 [0.0–33.0] | 15.0 [0.0–31.0] | 0.58 |
Functional capacity | |||
6MWD (metres) | 440.5 (125.7) | 347.3 (123.4) | 0.023 |
Lung function | |||
Vital capacity % | 99.2 (21.9) | 93.6 (13.1) | 0.40 |
Total lung capacity % | 110.2 (17.0) | 110.5 (23.5) | 0.96 |
Residual volume % | 132.0 (30.4) | 150.0 (55.9) | 0.16 |
Inspiratory capacity % | 93.1 (21.8) | 91.4 (20.9) | 0.81 |
FRC % | 125.6 (25.7) | 132.5 (45.9) | 0.52 |
DLCO % | 56.5 [40.0–102.0] | 61.5 [32.0–115.0] | 0.87 |
KCO % | 75.5 (80.1) | 74.7 (85.0) | 0.53 |
VA % | 81.4 (13.1) | 76.9 (14.2) | 0.29 |
Post FEV1 % | 68.2 (12.3) | 57.3 (12.8) | 0.002 |
Reversibility % | −4.4 [−53.8–+8.0] | −8.1 [17.3–+8.3] | 0.25 |
Reversibility mls | 20.0 [−170.0–580] | 90 [−120–200] | 0.90 |
Change in FEV1 from baseline | −80.0 [−420.0–+939.0] | −120.0 [−531.0–+180.0] | 0.07 |
Bacteriology | |||
Bacterial load (genome copies/ml) | 2.36 × 106 [0–8.89 × 108] | 10.3 × 107 [0–1.76 × 108] | 0.25 |
Colonised (% >1 × 104 total PPM) | 71.4 | 77.2 | 1.00 |
Systemic inflammation | |||
CRP (mg/L) | 3.0 [1.0–20.0] | 5.0 [2.0–20.0] | 0.017 |
WBC (109/L) | 6.9 [3.6–13.5] | 7.5 [4.8–11.8] | 0.73 |
Eosinophils (109/L) | 0.2 [0.1–0.6] | 0.2 [0.0–0.4] | 0.24 |